Chrysin enhances anticancer drug-induced toxicity mediated by the reduction of claudin-1 and 11 expression in a spheroid culture model of lung squamous cell carcinoma cells

Ryohei Maruhashi1, Hiroaki Eguchi1, Risa Akizuki1, Shohei Hamada2, Takumi Furuta2, Toshiyuki Matsunaga3, Satoshi Endo1, Kenji Ichihara4 & Akira Ikari1

The aberrant expression of claudins (CLDNs), which are tight junctional proteins, is seen in various solid tumors, but the regulatory mechanisms and their pathophysiological role are not well understood. Both CLDN1 and CLDN11 were highly expressed in human lung squamous cell carcinoma (SCC). Chrysin, found in high concentration in honey and propolis, decreased CLDN1 and CLDN11 expression in RERF-LC-Ai cells derived from human lung SCC. The phosphorylation level of Akt was decreased by chrysin, but those of ERK1/2 and c-Jun were not. LY-294002, an inhibitor of phosphatidylinositol 3-kinase, inhibited the phosphorylation of Akt and decreased the expression levels of CLDN1 and CLDN11. The association between phosphoinositide-dependent kinase 1 (PDK1) and Akt was inhibited by chrysin, but the phosphorylation of PDK1 was not. Immunoprecipitation and quartz-crystal microbalance assays revealed that biotinylated-chrysin binds directly to Akt. The knockdown of CLDN1 and CLDN11 using small interfering RNAs increased the transepithelial flux of doxorubicin (DXR), an anthracycline anticancer drug. Similarly, both chrysin and LY-294002 increased DXR flux. Neither CLDN1 knockdown, CLDN11 knockdown, nor chrysin changed the anticancer drug-induced cytotoxicity in a two-dimensional culture model, whereas they enhanced cytotoxicity in a spheroid culture model. Taken together, chrysin may bind to Akt and inhibit its phosphorylation, resulting in the elevation of anticancer drug-induced toxicity mediated by reductions in CLDN1 and CLDN11 expression in RERF-LC-Ai cells. We suggest that chrysin may be useful as an adjuvant chemotherapy in lung SCC.

Lung cancer is the leading cause of cancer death worldwide, and non-small-cell lung cancer (NSCLC) accounts for over 80% of lung cancers. NSCLC generally develops without symptoms or remarkable physical findings, and often presents at stages too late for surgical intervention. Approximately half of patients are diagnosed at a late stage. In addition, advanced NSCLC commonly exhibits resistance to chemotherapy and radiation1. Therefore, conventional systemic chemotherapy shows lower response rates in patients with NSCLC. Squamous cell carcinoma (SCC) is one histological subtype of NSCLC, accounting for 25–30% of NSCLC cases2. Recently, immune checkpoint inhibitors (ICIs) have been shown to improve overall survival in advanced NSCLC compared with standard treatment3. However, the efficacy of ICIs as a monotherapy for NSCLC is seen in only approximately 20% of patients4.

1Laboratory of Biochemistry, Department of Biopharmaceutical Sciences, Gifu Pharmaceutical University, Gifu, 501-1196, Japan. 2Department of Pharmaceutical Chemistry, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto, 607-8414, Japan. 3Education Center of Green Pharmaceutical Sciences, Gifu Pharmaceutical University, Gifu, 502-8585, Japan. 4Nagaragawa Research Center, API Co., Ltd., Gifu, 502-0071, Japan. Ryohei Maruhashi and Hiroaki Eguchi contributed equally. Correspondence and requests for materials should be addressed to A.I. (email: ikari@gifu-pu.ac.jp)
Cisplatin (DDDP), carboplatin, and oxaliplatin, are platinum-based drugs that are widely used in lung cancer chemotherapy. However, long-term application of chemotherapy may result in the development if acquired resistance in cells that were sensitive originally. Furthermore, acquired drug resistance can confer cross-resistance to a wide range of compounds that have no obvious structural or functional similarities, thereby causing inefficient treatment. Over 50% of patients undergoing lung cancer surgery acquire a chemoresistant phenotype. A variety of mechanisms including mutation in the target molecule of anticancer drugs, induction of drug efflux pumps and drug-metabolizing enzymes, and DNA epigenetic states are involved in the development of drug resistance. The establishment of a tumor microenvironment, which consists of leukocytes, extracellular matrix, endothelial cells, and so on, is also involved in the development of chemoresistance, but the molecular mechanisms remain elusive. A spheroid is a three-dimensional (3D) in vitro tumor model that resembles the in vivo situation. We recently reported that claudin-1 (CLDN1), CLDN2, and occludin, components of tight junctions (TJs), decrease chemosensitivity to doxorubicin (DXR), an anthracycline anticancer drug, in 3D cultured lung adenocarcinoma A549 cells. The expression levels of CLDN3, 4, 5, 7, and 18 are down-regulated in human lung SCC tissue and in RERF-LC-AI cells, which are derived from human lung SCC, compared with normal lung tissue, whereas CLDN1 is highly expressed. However, the pathophysiological role of the abnormal expression of CLDNs is not yet fully understood.

Flavonoids are dietary phenolic compounds found ubiquitously in plant foods such as fruits and vegetables. Most flavonoids have anti-oxidant, anti-proliferative, and anti-tumor activities. Chrysin is a natural flavonoid contained in various plants and propolis. Chrysin inhibits proliferation and induces apoptosis by inhibiting Akt activation in NSCLC cells. The chemopreventive effects of chrysin have been reported in hepatocellular carcinoma, anaplastic thyroid cancer, breast carcinoma, and prostate carcinoma xenograft mice models. In addition, chrysin has the potential to enhance and improve the chemo sensitivity of NSCLC cells to anticancer drugs. However, the anticancer mechanisms of chrysin have not been fully elucidated.

Human SCC tissue and RERF-LC-AI cells derived from human lung SCC express not only CLDN1, but also CLDN11 at high levels. Therefore, we investigated their pathophysiological roles and searched for compounds that can decrease CLDN1 and CLDN11 expression. Chrysin decreased the expression of CLDN1 and CLDN11 mediated by the inhibition of Akt. The direct interaction of chrysin with Akt was observed by the immunoprecipitation and quartz crystal microbalance (QCM) assays. Chrysin enhanced anticancer agent-induced toxicity in a 3D spheroid culture model with RERF-LC-AI cells. Our data indicate that chrysin is a potential compound for the adjuvant treatment of human SCC.

**Results**

**Expression of CLDN1 and CLDN11 in human lung SCC and RERF-LC-AI cells.** We reported previously that CLDN1 is highly expressed in human lung SCC tissue and RERF-LC-AI cells, whereas the expression levels of CLDN3, 4, 5, 7, and 18 were lower than those in normal tissue. Here, we found that CLDN11 is also highly expressed in human lung SCC tissue and RERF-LC-AI cells (Fig. 1). CLDNs are scaffolded by zonula occludens-1 (ZO-1), which interacts with the actin cytoskeleton. Both CLDN1 and CLDN11 were colocalized with ZO-1, but the images showed punctate staining of CLDNs and ZO-1 in the cell-cell border area.

**Effects of knockdown of CLDN1 and CLDN11 on sensitivity to anticancer drugs.** The pathophysiological roles of CLDN1 and CLDN11 have not been fully clarified in lung SCC cells. We examined the effects of CLDN1 and CLDN11 knockdown on anticancer agent-induced cytotoxicity. The introduction of small interfering RNAs (siRNAs) for CLDN1 and CLDN11 suppressed the protein expression of CLDN1 and CLDN11, respectively (Fig. 2A). DXR and CDDP increased cytotoxicity in a dose-dependent manner (Fig. 2B). Neither CLDN1 nor CLDN11 knockdown significantly changed the sensitivity to DXR and CDDP. Anticancer-induced cytotoxicity was diminished by the activation of their extrusion through ABC transporters. Neither CLDN1 nor CLDN11 knockdown significantly changed the protein levels of ABCB1, ABCC1, or ABCG2 (Fig. 2C). The expression of ABCB2 was detected in positive control A549 cells, but not in RERF-LC-AI cells. These results indicated that neither CLDN1 nor CLDN11 is involved in chemosensitivity in this 2D culture model.

**Effects of sodium caprate (CA) and knockdown of CLDN on transepithelial permeability.** CLDN subtypes can form homo- or heterophilic interactions between adjacent cells and regulate paracellular solute and ion transport. Transepithelial electrical resistance (TER) was increased after days 2 and made a plateau phase (Fig. 3A). TER was significantly decreased by CA, a TJ’s modulator (Fig. 3B). In addition, transepithelial fluxes of lucifer yellow, a fluorescent marker for the paracellular pathway, and DXR were increased by CA (Fig. 3C). Both TER and transepithelial fluxes of lucifer yellow were changed by CA, but RERF-LC-AI cells did not form continuous TJs and their TJ barrier was incomplete. Both CLDN1 and CLDN11 knockdown increased transepithelial permeability to DXR without changing TER (Fig. 3D,E). These results indicated that CLDN1 and CLDN11 may not be involved in the regulation of paracellular ion permeability, but they may suppress paracellular permeability for small molecules.

**Increase in DXR sensitivity by knockdown of CLDN1 and CLDN11 in a 3D spheroid model.** Neither CLDN1 nor CLDN11 changed spheroid sizes, but they significantly decreased hypoxia levels (Fig. 4A,B). The fluorescence intensity of DXR in the spheroids was increased in a dose dependent manner, indicating that DXR accumulated in the spheroids (Fig. 4C). The accumulation of DXR was significantly enhanced by CLDN1 and CLDN11 knockdown. DXR decreased the viability of spheroid cells in a dose-dependent manner, which was enhanced by CLDN1 and CLDN11 knockdown (Fig. 4D). These results indicated that both CLDN1 and CLDN11 may be involved in chemoresistance in 3D spheroid cells.
Effect of luteolin and chrysin on the expression of CLDN1 and CLDN11 in RERF-LC-AI cells. Many flavonoids have been reported to have anticancer activity. We examined the effect of some flavonoids contained in extracts of propolis on CLDN expression. Cell viability was decreased by luteolin in a dose-dependent manner between 5 and 50 μM and by chrysin above 50 μM (Fig. 5A). The protein and mRNA levels of CLDN11 were decreased by both 10 μM luteolin and 10 μM chrysin, whereas those of CLDN1 were decreased by chrysin only (Fig. 5B, C). The protein levels of CLDN1 were not decreased by quercetin or kaempferol (data not shown). Therefore, we tried to clarify the molecular mechanism of action of chrysin.

Involvement of Akt in the regulation of CLDN1 expression. There are no reports on what intracellular signaling factors are involved in CLDN1 and CLDN11 expression in lung SCC cells. Chrysin did not change p-ERK1/2 or p-c-Jun levels, whereas it decreased p-Akt levels (Fig. 6A). The phosphorylation of Akt is upregulated by phosphoinositide-dependent kinase 1 (PDK1), a kinase functioning downstream of phosphatidylinositol 3-kinase (PI3K). However, p-PDK1 levels were not changed by chrysin. The total amounts of Akt, PDK1, ERK1/2, and c-Jun were not changed by chrysin. LY-294002, an inhibitor of the PI3K/Akt signaling pathway, significantly decreased p-Akt, CLDN1, and CLDN11 levels (Fig. 6B, C). In addition, the mRNA levels of CLDN1 and CLDN11 were decreased by LY-294002 (Fig. 6D). These results coincided with those using chrysin.

Inhibition of the association between PDK1 and Akt by chrysin. To clarify the direct interaction of chrysin, we synthesized biotinylated-chrysin (Fig. 7A). In immunoprecipitation assays, biotinylated-chrysin bound to Akt, but not to PDK1 (Fig. 7B). In addition, QCM analysis showed that biotinylated-chrysin bound to...
human recombinant Akt (Fig. 7C). Akt was associated with PDK1, which was significantly inhibited by chrysin (Fig. 7D). In contrast, the level of immunoprecipitated PDK1 was not changed by chrysin. These results indicated that chrysin may inhibit phosphorylation of Akt and interaction of Akt with PDK1 mediated by direct association with Akt.

Figure 2. Effect of knockdown of CLDN1 and CLDN11 on the cytotoxicity of anticancer drugs. RERF-LC-AI cells were transfected with siRNAs for a negative control (si-Nega), CLDN1 (si-C1), or CLDN11 (si-C11). (A) The expression levels of CLDN1, CLDN11, and β-actin in cell lysates were examined by western blotting. The protein levels are shown as a percentage of values in the negative control siRNA (si-Nega). (B) Cytotoxicity was measured using WST-1 assays. (C) The expression levels of ABCB1, ABCC1, ABCG2, ABCC2, and β-actin in cell lysates were examined by western blotting. A549 cells were used as a positive control in the detection of ABCC2. The protein levels without ABCC2 are shown as a percentage of values in the negative control siRNA (si-Nega). The full-length blot images are shown in Supplementary Fig. S1. n = 3–6. **P < 0.01 and NS, P > 0.05 compared with the negative control siRNA.
Effects of chrysin on sensitivity and transepithelial permeability to anticancer drugs. As shown in Fig. 5A, chrysin did not show cytotoxicity at 10 μM. Chrysin slightly suppressed the DXR-induced cytotoxicity at 3–10 μM, whereas it did not affect CDDP-induced cytotoxicity (Fig. 8A). Next, we examined the effects of chrysin and LY-294002 on transepithelial permeability. Both chrysin and LY-294002 increased transepithelial permeability to DXR without changing TER (Fig. 8B). These results coincided with those using CLDN1 and CLDN11 knockdown.

Increase in DXR and CDDP toxicities of spheroid cells by chrysin. Chrysin did not change spheroid size, but it significantly decreased hypoxia levels (Fig. 9A,B). The accumulation of DXR in the spheroids was significantly enhanced by chrysin (Fig. 9C). DXR and CDDP decreased the viability of spheroid cells in a dose-dependent manner, which was enhanced by chrysin (Fig. 9D,E). These results coincided with those using CLDN1 and CLDN11 knockdown. Chrysin may enhance the sensitivity to anticancer drugs in 3D spheroid cells mediated by the reduction in CLDN1 and CLDN11 expression. To support the idea, we examined the effect of CLDN1 overexpression on the accumulation and toxicity of DXR. The chrysin-induced elevation of accumulation and toxicity of DXR was significantly inhibited by CLDN1 overexpression (Fig. 10).

Discussion
Normal lung epithelia expresses CLDN1, 3, 4, 5, 7, and 18, but not CLDN11. We reported previously that the expression of CLDN1 is upregulated in human SCC tissue and RERF-LC-AI cells compared with normal tissue, whereas CLDN3, 4, 5, 7, and 18 are downregulated. Here, we found that CLDN11 is highly expressed in SCC (Fig. 1). Immunofluorescence and TER measurements showed the cells form incomplete TJs. However, transepithelial fluxes of lucifer yellow and DXR were increased by the treatment with CA or introduction of siRNA for CLDN1 and CLDN11, suggesting that the cells can form partially functional TJs barrier. The elevation of CLDN1 expression was reported in various carcinoma tissues including colon, stomach, and pancreas. Similar to our results, Paschoud et al. reported that the mRNA and protein levels of CLDN1 in SCC are higher than those in parenchyma. However, their report indicated no correlation between the expression of CLDN1 and the clinicopathological characteristics of SCC.

The downregulation of CLDN3 and CLDN7 is associated with poor prognosis and poor survival in patients with SCC, respectively. The overexpression of CLDN5, 7, and 18 suppresses cell cycle progression from G1 to S phase in RERF-LC-AI cells, indicating that these CLDNs are involved in the regulation of SCC cell proliferation. In contrast, the pathophysiological roles of CLDN1 and CLDN11 in SCC are not fully understood. We reported recently that the expression of CLDN1 is exaggerated by CDDP resistance in A549 cells. The
knockdown of CLDN1 and CLDN11 expression by siRNA increased the transepithelial flux of DXR, but it did not significantly change anticancer drug-induced toxicity or the expression of ABC transporters in a 2D culture model of RERF-LC-AI cells (Figs 2 and 3), suggesting that neither CLDN1 nor CLDN11 are directly involved in chemoresistance against anticancer drugs.

The PI3K/Akt signaling pathway is mainly involved in the regulation of cell survival and apoptosis35, and the activation of Akt has been reported in over 60% of NSCLC patients 36. Both CLDN1 and CLDN11 expression levels were decreased by LY-294002 (Fig. 6), suggesting that their expression is upregulated by Akt in SCC cells. Similarly, the expression of CLDN1 is upregulated by Akt in A54919 and cervical adenocarcinoma cells37. In contrast, an inverse relationship between phosphorylation of Akt and CLDN1 expression is reported in esophageal SCC cells38. The regulatory mechanism of CLDN1 expression may differ according to the type of carcinoma. On the other hand, there are no reports showing whether Akt is involved in the regulation of CLDN11 expression. Notably, chrysin decreased both CLDN1 and CLDN11 expression (Fig. 5). Furthermore, chrysin significantly decreased p-Akt levels, but did not change p-ERK1/2 and p-c-Jun levels. We suggest that chrysin decreases both CLDN1 and CLDN11 in RERF-LC-AI cells mediated by the inhibition of p-Akt.

Chrysin shows a preventive effect on cancer mediated by various mechanisms including reduction in the activities of cytochrome P450-dependent monooxygenases, induction of the activity of antioxidant and detoxification enzymes, inhibition of cellular proliferation, and induction of apoptosis39. The phenotype of cancer cells is regulated by diverse signaling molecules including the Akt pathway. Chrysin decreased p-Akt levels without affecting the total amount of Akt or phosphorylation of PDK1 (Fig. 6A). The inhibition of Akt by chrysin has been reported in A54912, breast cancer40 and leukemia cells41. Therefore, it is suggested that chrysin binds to Akt, although there was no direct evidence showing this as yet. Immunoprecipitation and QCM assays revealed that biotinylated chrysin can bind directly to Akt (Fig. 7B,C). The association between PDK1 and Akt was inhibited by chrysin (Fig. 7D). Thus, our data provide the first indication that chrysin can interact directly with Akt, resulting in inhibition of the phosphorylation of Akt and association of PDK1 with Akt.

The knockdown of CLDN1 and CLDN11 by siRNA enhances DXR accumulation and DXR-induced toxicity in 3D spheroid cells (Fig. 4). Similar results were observed using treatment with chrysin (Fig. 9B). Transepithelial flux of DXR was negatively regulated by CLDN1 and CLDN11. The accumulation and toxicity of DXR was...
significantly suppressed by CLDN1 overexpression (Fig. 10). We suggest that CLDN1 or CLDN11 overexpression impaired tumor sensitivity to anticancer drugs mediated by interference with penetration of the drugs into inner areas of the spheroid. Another explanation is that both CLDN1 and CLDN11 induce chemoresistant characteristics of cancer cells. Hypoxia levels of spheroid were inversely changed by CLDN1 and CLDN11 expression (Fig. 4). Cancer cells form microenvironment in vivo, and the inner cells of the microenvironment are exposed to nonlethal hypoxia and oxidative stress, which has significant effects on tumor progression and treatment efficacy. These findings raise a possibility that the alleviation of hypoxic conditions by decreasing in the expression of CLDN1 and CLDN11 improves chemosensitivity in spheroid cells. High interstitial fluid pressure, increased collagen production, and poorly formed vasculature exacerbate hypoxia42. However, it is unknown what mechanisms are involved in the establishment of hypoxic conditions in vitro in spheroids. Further studies are needed to clarify how CLDN and chrysin improve them, but chrysin may be useful to improve hypoxia and suppress the malignancy of SCC cells.

In conclusion, we found that human SCC tissue and RERF-LC-AI cells exhibit high expression levels of not only CLDN1 but also CLDN11 compared with normal tissue. Chrysin inhibited the phosphorylation of Akt and decreased the expression levels of CLDN1 and CLDN11 similar to LY-294002. Immunoprecipitation and QCM

Figure 5. Effect of luteolin and chrysin on the expression levels of CLDN1 and CLDN11. (A) RERF-LC-AI cells were treated with luteolin or chrysin at the indicated concentrations for 24 h. Cytotoxicity was measured using WST-1 assays. (B) The cells were treated with 10μM luteolin (Lut) or 10μM chrysin (Chr) for 24 h. The expression levels of CLDN1, CLDN11, and β-actin in cell lysates were examined by western blotting. The protein levels of CLDN1 and CLDN11 are shown as a percentage of values in the control cells (Cont). The full-length blot images are shown in Supplementary Fig. S2. (C) The cells were treated with 10μM luteolin or 10μM chrysin for 6 h. The mRNA levels of CLDN1 and CLDN11 are shown as a percentage of the values in control cells. n = 3–4. **P < 0.01, *P < 0.05, and NS, P > 0.05 compared with 0μM or the control.
assays showed that chrysin binds directly to Akt and inhibits the association of PDK1 with Akt. Chrysin increased transepithelial flux of DXR without affecting TER. In addition, chrysin did not change anticancer agent-induced toxicity in a 2D model, but it enhanced toxicity in a 3D spheroid model. Our data indicate that chrysin may be a potential compound for adjuvant treatment of human SCC.

**Material and Methods**

**Materials.** Antibodies used in the present experiments were listed in Table 1. Chrysin, Lipofectamine 2000, luteolin, LY-294002, and human recombinant Akt were obtained from Tokyo Kasei Kogyo (Tokyo, Japan), Thermo Fisher Scientific (Rockford, IL, USA), INDOFINE Chemical Company (Hillsborough, NJ, USA), BIOMOL Research Laboratories (Plymouth Meeting, PA, USA), and ProSpec-Tany TechnoGene (Rehovot, Israel), respectively. CDDP, DXR, and ScreenFect A were from Wako Pure Chemical (Osaka, Japan). All other reagents were of the highest purity commercially available.

**2D and 3D Cell culture.** RERF-LC-AI cells (RIKEN BRC through the National Bio-Resource Project of the MEXT, Ibaraki, Japan) were cultured as described previously. For 3D culture, the cells were plated at densities of \(1 \times 10^4\) cells/well on PrimeSurface96V multi-well plates (Sumitomo Bakelite, Tokyo, Japan). After culturing for 96 h, the size and viability of spheroids were measured as described previously. The fluorescence intensities of DXR and LOX-1, a hypoxia probe, were calculated using ImageJ software.

**siRNA and transfection.** siRNAs for negative control and CLDNs were obtained from Santa Cruz and Sigma-Aldrich, respectively. The siRNAs were transfected into 2D and 3D cultured cells using Lipofectamine 2000 and ScreenFect A, respectively.
Cell viability assay in 2D culture. Cells were seeded at densities of \(7 \times 10^3\) cells on 96-well flat bottomed plates. Chrysin, luteolin, and anticancer drugs were applied for 24 h in FCS-free media. The cell viability was measured using a Premix WST-1 Cell Proliferation Assay Kit (Takara, Otsu, Japan).

Isolation of total RNA and quantitative real-time polymerase chain reaction. Total RNA was extracted from cells using TRI reagent (Sigma-Aldrich). To compare the expression of CLDNs between human normal lung and RERF-LC-AI cells, we used three independent mRNAs of normal lung tissue (Clontech Laboratories, Mountain View, CA, USA, Agilent Technologies, Santa Clara, CA, USA, and BioChain Institute, Hayward, CA, USA). The expression of CLDNs between human normal lung and SCC tissues were investigated.
using Lung Cancer cDNA Array II and V (OriGene, Rockville, MD, USA). Reverse transcription was carried out using a ReverTra Ace qPCR RT Kit (Toyobo Life Science, Osaka, Japan). Quantitative real-time PCR was performed using an Eco Real-Time polymerase chain reaction (PCR) system (AS One, Osaka, Japan) with a THUNDERBIRD SYBR qPCR Mix (Toyobo Life Science). The primers used for PCR are listed in Table 2. The relative change in mRNA expression was calculated as described previously.

**Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and western blotting.** Confluent cells were scraped into cold phosphate-buffered saline and precipitated by centrifugation. Then, the cells were lysed in a RIPA buffer (150 mM NaCl, 50 mM Tris-HCl (pH 8.0), 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 0.5 mM EDTA) supplemented with a protease inhibitor cocktail (Sigma-Aldrich), and sonicated for 20 s. Nuclear fraction was removed by centrifugation at 6,000 × g for 5 min. The resultant supernatants were used as cell lysates. SDS-polyacrylamide gel electrophoresis and western blotting were carried out as described previously.

Figure 8. Effects of chrysin and CA-Akt on anticancer drug-induced cytotoxicity and tight junction permeability. (A) RERF-LC-AI cells were treated with DXR or CDDP in the presence or absence of 10 μM chrysin (Chr) for 24 h. Cytotoxicity was measured using WST-1 assays. (B) The cells were plated on transwell inserts and treated with 10 μM chrysin or 20 μM LY-294002. TER and transepithelial DXR flux were analyzed using a volt ohmmeter and fluorescence spectrometry, respectively. (C) The cells were transfected with mock or CA-Akt vector, and then treated with 10 μM chrysin. TER and transepithelial DXR flux were analyzed. n = 3–4. **P < 0.01, *P < 0.05, and NS, P > 0.05 compared with the control.
immunoprecipitation. Cell lysates were incubated with Protein G-sepharose (GE Healthcare, Bucks, UK) and anti-PDK1 antibodies for 16 h at 4 °C using a rotator. In the case using biotinylated-chrysin, cell lysates were incubated with or without biotinylated-chrysin in the presence of avidin agarose (Thermo Fisher Scientific). Immunoprecipitants were washed four times with an immunoprecipitation buffer (150 mM NaCl, 0.5 mM EDTA, 0.5% Triton X-100, 50 mM Tris-HCl (pH 7.4), and a protease inhibitor cocktail) and then subjected to SDS-polyacrylamide gel electrophoresis.

confocal microscopy. Immunofluorescence measurements were carried out as described previously. Measurement of transepithelial permeability. Cells were seeded at densities of 5 × 10⁴ cells on Transwells (0.4 μm pore size, 12 mm diameter) with polyester membrane inserts (Corning Incorporated, Corning, NY, USA). TER and paracellular flux of lucifer yellow and DXR were measured as described previously. Synthesis of biotinylated chrysin. Preparation of chrysin azide. To a solution of 7-O-carboxymethyl chrysin (100 mg, 0.32 mmol), 3-azidopropan-1-amine (65 mg, 0.61 μmol), and EDCI (117 mg, 0.61 mmol) in DMF (2.0 mL) was added and DMAP (6.0 mg, 49 μmol) at room temperature (rt) in an Ar atmosphere. After being stirred for 12 h at rt, DMAP (60 mg, 0.49 mmol) was further added, and the reaction mixture was warmed to 70 °C. Even after stirring for 6 h at 70 °C, 7-O-carboxymethyl chrysin was still present. Therefore, 3-azidopropan-1-amine (40 mg, 0.40 μmol) was added and stirred for 15 h at 70 °C. 3-Azidopropan-1-amine (40 mg, 0.40 μmol) was further added and stirred for 6 h at 80 °C. The reaction mixture was diluted with AcOEt, washed with saturated aqueous NH₄Cl and brine. The organic layer was dried over Na₂SO₄, filtered, and evaporated in vacuo to give a residue. The residue was crystallized from hexane-CHCl₃ to afford chrysin azide as colorless prisms (55 mg, 29%).

Colorless prisms (hexane-CHCl₃); Mp 144–145 °C. ¹H nuclear magnetic resonance (NMR; 300 MHz, CDCl3) δ (quin, J = 6.5 Hz, 2H), 3.41 (t, J = 6.5 Hz, 2H), 3.48 (q, J = 6.5 Hz, 2H), 4.58 (s, 2H), 6.41 (d, J = 2.3 Hz, 1H), 6.53 (d, J = 2.3 Hz, 1H), 7.70 (s, 1H), 6.65–6.80 (m, 2H), 7.40–7.61 (m, 3H), 7.83–7.93 (m, 2H), 12.77 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 28.7, 37.0, 49.4, 67.4, 93.0, 99.0, 105.0, 106.5, 126.4, 129.2, 131.1, 132.1, 157.8, 162.5, 162.7, 164.4, 167.2, 182.5; IR (ATR) 2085, 1658, 1606 cm⁻¹; MS (FAB) m/z 395 (M + H)⁺; HRMS (FAB) m/z calcd for C₂₀H₁₉N₄O₅ (M + H)⁺ 395.1355, found 395.1356.

Figure 9. Increase in anticancer-induced toxicity by chrysin in a spheroid model. RERF-LC-AI cells were plated on PrimeSurface96V multi-well plates, and then treated with or without 10 μM chrysin (Chr) for 24 h. (A, B) The spheroid size and fluorescence intensity of LOX-1 are represented as a percentage of the values in the control (Cont). (C) The cells were incubated with DXR for 60 min at the concentrations indicated. The fluorescence intensities of DXR in spheroids are shown as a percentage of the values in 0 μM. (D, E) After treating the cells with DXR or CDDP for 24 h at the concentrations indicated, the viability of spheroid cells was measured. These values are represented as a percentage of the control. n = 3–4. *P < 0.05 and NS, P > 0.05 compared with the control.
Figure 10. Inhibition of chrysin-induced elevation of toxicity by CLDN1 overexpression in a spheroid model. RERF-LC-AI cells were plated on PrimeSurface96V multi-well plates, and then transfected with mock or CLDN1 expression vector. (A) The cells were incubated with DXR for 60 min at the concentrations indicated in the presence or absence of 10 μM chrysin. The fluorescence intensities of DXR in spheroids are shown as a percentage of the values in 0 μM. (B) After treating the cells with DXR for 24 h at the concentrations indicated in the presence or absence of chrysin, the viability of spheroid cells was measured. These values are represented as a percentage of mock. n = 3–4. **P < 0.01 and *P < 0.05 compared with mock. ##P < 0.01, #P < 0.05 and NS, P > 0.05 compared with mock (Chr).

| Name     | Sources     | Catalog No. | Suppliers                                      |
|----------|-------------|-------------|------------------------------------------------|
| p-Akt    | Rabbit      | 4060        | Cell Signaling Technology (Beverly, MA, USA)   |
| Akt      | Rabbit      | 4691        |                                                 |
| ERK1/2   | Rabbit      | 4695        |                                                 |
| ABC2     | Rabbit      | 4446        |                                                 |
| p-PDK1   | Rabbit      | 5241        |                                                 |
| PDK1     | Rabbit      | 3062        |                                                 |
| β-Actin  | Goat        | sc-1615     | Santa Cruz Biotechnology (Santa Cruz, CA, USA)  |
| p-ERK1/2 | Rabbit      | sc-16982R   |                                                 |
| ABCB1    | Rabbit      | GTX108354   | GeneTex (Irvine, CA, USA)                       |
| ABCG1    | Rabbit      | GTX116046   |                                                 |
| ABCG2    | Rabbit      | GTX100437   |                                                 |
| ZO-1     | Mouse       | 33–9100     | Thermo Fisher Scientific (Rockford, IL, USA)    |

Table 1. Lists of antibodies.

| Genes    | Direction | Sequence                        |
|----------|-----------|---------------------------------|
| CLDN1    | Sense     | 5′-ATGAGGATGGCTGTCATTGG-3′      |
| CLDN1    | Antisense | 5′-ATTGACTGGGGTTCATAGGTT-3′     |
| CLDN11   | Sense     | 5′-ACGGGGCTGTTACCAGTGC-3′       |
| CLDN11   | Antisense | 5′-CAGGACCCAGGGCAATCATCAG-3′    |
| β-Actin  | Sense     | 5′-CCTGAGGCACTCTTCCAGCTT-3′     |
| β-Actin  | Antisense | 5′-TTCCGATGTCAGCAGCATCTC-3′     |

Table 2. Primers for real-time PCR.
Preparation of biotinylated chrysin. To a solution of chrysin azide (45 mg, 0.11 mmol), biotin-alkyne conjugate (32 mg, 0.11 μmol), and CuTC (4.3 mg, 23 μmol) in CH₂Cl₂ (3.0 mL)-MeOH (0.3 mL) was added and stirred for 12 h at rt in an Ar atmosphere. The reaction mixture was evaporated in vacuo to give a residue. The residue was successively washed with H₂O, CHCl₃, and MeOH. The washed residue was dissolved in DMF (2.0 mL), and silica gel for column chromatography (2.0 g) was added and evaporated in vacuo to afford the residue adsorbed on silica gel. This residue was applied to silica gel column and eluted with CHCl₃/MeOH (5:1) to give a solid. This solid was further washed with CHCl₃ to give biotinylated chrysin as pale yellow solid (20 mg, 26%).

1H NMR (300 MHz, DMSO-d₆) δ 1.21–1.35 (m, 2H), 1.38–1.67 (m, 4H), 1.90 (quint, J = 6.9 Hz, 2H), 2.09 (t, J = 7.4 Hz, 2H), 2.57 (d, J = 12.5 Hz, 1H), 2.81 (dd, J = 5.0 Hz, 12.5 Hz, 1H), 3.04–3.12 (m, 1H), 3.15–3.23 (m, 2H), 4.08–4.15 (m, 1H), 4.22–4.40 (m, 5H), 4.66 (s, 2H), 6.36 (s, 1H), 6.41 (s, 1H), 6.46 (d, J = 2.2 Hz, 1H), 6.85 (d, J = 2.2 Hz, 1H), 7.07 (s, 1H), 7.55–7.68 (m, 3H), 7.91 (s, 1H), 8.07–8.13 (m, 2H), 8.21–8.33 (m, 2H), 12.82 (s, 1H); 13C NMR (125 MHz, DMSO-d₆) δ 25.2, 28.0, 28.2, 29.9, 34.1, 35.0, 35.8, 47.1, 55.4, 59.2, 61.0, 67.2, 79.0, 79.2, 93.7, 98.9, 105.4, 105.5, 122.9, 126.6, 129.3, 130.7, 145.1, 157.4, 157.6, 162.0, 163.0, 163.7, 163.8, 167.1, 182.3; IR (ATR) 1702, 1658, 1614 cm⁻¹; MS (ESI) m/z calc'd for C₃₀H₂₈N₇O₇S (M + H)⁺ 676.2548, found 676.2542.

A quartz-crystal microbalance analysis. Avidin was deposited on the Au electrode of a QCM twin sensor chip ((Nihon Dempa Kogyo, Tokyo, Japan), which consists of two channels (CH1 and CH2). CH1 and CH2 were modified with biotin and biotinylated-chrysin, respectively. Human recombinant Akt (5 μg/ml) was injected into the flow cell at a flow rate of 50 μl/min. Detection of the association between chrysin and Akt was carried using a QCM sensor system. Sensor response was measured by subtracting the frequency shifts of CH2 from CH1.

Statistical analysis. Results are presented as means ± standard error mean. Statistical analyses were performed using KaleidaGraph version 4.5.1 software (Synergy Software, PA, USA) as described previously. Significant differences were accepted at p < 0.05.

References
1. Sechler, M. et al. Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategies. Pharmgenomics Pers. Med. 6, 25–36 (2013).
2. Cancer Genome Atlas Research. N. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519–525 (2012).
3. Horn, L. et al. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J. Clin. Oncol. 35, 3924–3933 (2017).
4. Sui, H. et al. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. Journal of immunology research 2018, 6984984 (2018).
5. Castells, M., Thibault, B., Delord, J. P. & Couderc, B. Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. International journal of molecular sciences 13, 9545–9571 (2012).
6. Kartal-Yandim, M., Adan-Gokbulut, A. & Baran, Y. Molecular mechanisms of drug resistance and its reversal in cancer. Crit. Rev. Biotechnol. 36, 716–726 (2016).
7. Senthebane, D. A. et al. The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer. International journal of molecular sciences 18 (2017).
8. Longati, P. et al. 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing. BMC Cancer 13, 95 (2013).
9. Maruhashi, R. et al. Elevation of sensitivity to anticancer agents of human lung adenocarcinoma A549 cells by knockdown of claudin-2 expression in monolayer and spheroid culture models. Biochim. Biophys. Acta 1865, 470–479 (2018).
10. Akizuki, R. et al. Decrease in paracellular permeability and chemosensitivity in human lung adenocarcinoma cells by claudin-1 in spheroid culture models. Biochim. Biophys. Acta 1865, 769–780 (2018).
11. Middleton, E. Jr., Kandaswami, C. & Theoharides, T. C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol. Rev. 52, 673–751 (2000).
12. Shao, J. et al. AMP-activated protein kinase (AMPK) activation is involved in chrysin-induced growth inhibition and apoptosis in cultured A549 lung cancer cells. Biochem. Biophys. Res. Commun. 423, 448–453 (2012).
13. Khoob, B. Y., Chua, S. L. & Balaram, P. Apoptotic effects of chrysin in human cancer cell lines. International journal of molecular sciences 11, 2188–2199 (2010).
14. Xu, D. et al. Chrysin inhibited tumor glycolysis and induced apoptosis in hepatocellular carcinoma by targeting hexokinase-2. J. Exp. Clin. Cancer Res. 36, 44 (2017).
15. Yu, X. M., Phan, T., Patel, P. N., Jaskula-Sztul, R. & Chen, H. Chrysin activates Notch1 signaling and suppresses tumor growth of anaplastic thyroid carcinoma in vitro and in vivo. Cancer 119, 774–781 (2013).
16. Sun, L. P. et al. Chrysin: a histone deacetylase 8 inhibitor with anticancer activity and a suitable candidate for the standardization of Chinese propolis. J. Agric. Food Chem. 60, 11748–11758 (2012).
17. Fu, B. et al. Chrysin inhibits expression of hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability and inhibiting its protein synthesis. Mol. Cancer Ther. 6, 220–226 (2007).
18. Lim, H. K., Kim, K. M., Jeong, S. Y., Choi, E. K. & Jung, J. Chrysin Increases The Therapeutic Efficacy of Docetaxel and Mitigates Docetaxel-Induced Edema. Integ. Cancer Ther. 16, 496–504 (2017).
19. Akizuki, R., Shimobaba, S., Matsunaga, T., Endo, S. & Ikari, A. Claudin-5, -7, and -18 suppress proliferation mediated by inhibition of phosphorylation of Akt in human lung squamous cell carcinoma. Biochim. Biophys. Acta 1864, 293–302 (2017).
20. Witschen, E. S., Haskins, J. & Stevenson, B. R. Protein interactions at the tight junction. Actin has multiple binding partners, and ZO-1 forms independent complexes with ZO-2 and ZO-3. J. Biol. Chem. 274, 35179–35185 (1999).
21. Furuse, M. Molecular basis of the core structure of tight junctions. Cold Spring Harb. Perspect. Biol. 2, a002907 (2010).
22. Domenichini, A., Adan-Gokbulut, A. & Baran, Y. Molecular mechanisms of drug resistance and its reversal in cancer. Crit. Rev. Oncogenc 27, 6930–6938 (2008).
23. Powell, D. W. Barrier function of epithelia. Am. J. Physiol. 241, G275–G288 (1981).
24. Matter, K. & Balda, M. S. Signalling to and from tight junctions. Nat. Rev. Mol. Cell Biol. 4, 225–236 (2003).
26. Raffa, D., Maggio, B., Raimondi, M. V., Plescia, F. & Daidone, G. Recent discoveries of anticancer flavonoids. *Eur. J. Med. Chem.* 142, 213–228 (2017).

27. Coyne, C. B., Gambling, T. M., Boucher, R. C., Carson, J. L. & Johnson, L. G. Role of claudin interactions in airway tight junctional permeability. *Am. J. Physiol. Lung Cell Mol. Physiol.* 285, L1166–L1178 (2003).

28. Daugherty, B. L. *et al.* Developmental regulation of claudin localization by fetal alveolar epithelial cells. *Am. J. Physiol. Lung Cell Mol. Physiol.* 287, L1266–L1273 (2004).

29. Miwa, N. *et al.* Involvement of claudin-1 in the beta-catenin/Tcf signaling pathway and its frequent upregulation in human colorectal cancers. * Oncol. Res.* 12, 469–476 (2001).

30. Resnick, M. B. *et al.* Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. *Hum. Pathol.* 36, 886–892 (2005).

31. Iacobuzio-Donahue, C. A. *et al.* Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. *Am. J. Pathol.* 160, 1239–1249 (2002).

32. Paschoud, S., Bongiovanni, M., Pache, J. C. & Citi, S. Claudin-1 and claudin-5 expression patterns differentiate lung squamous cell carcinomas from adenocarcinomas. *Mod. Pathol.* 20, 947–954 (2007).

33. Che, J. *et al.* Decreased expression of claudin-3 is associated with a poor prognosis and EMT in completely resected squamous cell lung carcinoma. *Tumour Biol.* 36, 6539–6568 (2015).

34. Yamamoto, T. *et al.* Reduced expression of claudin-7 is associated with poor outcome in non-small cell lung cancer. *Oncol. Lett.* 1, 501–505 (2010).

35. Yip, P. Y. Phosphatidylidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer. *Translational lung cancer research* 4, 165–176 (2015).

36. Lee, S. H. *et al.* Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study. *APMIS* 110, 587–592 (2002).

37. Akimoto, T. *et al.* Expression of Claudin-1 in the malignant and inflammatory conditions of the cervical epithelium. *Neoplasia* 5, e239 (2016).

38. Kuo, K. T. *et al.* Nm23H1 mediates tumor invasion in esophageal squamous cell carcinoma by regulation of CLDN1 through the AKT signaling. *Oncogenesis* 5, e239 (2016).

39. Kasala, E. B. *et al.* Chemopreventive and therapeutic potential of chrysins in cancer: mechanistic perspectives. *Toxicol. Lett.* 233, 214–225 (2015).

40. Yang, B. *et al.* Chrysin inhibits metastatic potential of human triple-negative breast cancer cells by modulating matrix metalloproteinase-10, epithelial to mesenchymal transition, and PI3K/Akt signaling pathway. *J. Appl. Toxicol.* 34, 105–112 (2014).

41. Woo, K. J. *et al.* The relationship between Claudin-1 expression and epithelial mesenchymal transition in human colorectal cancers. *Oncol. Lett.* 6, 1239–1249 (2013).

42. Daugherty, B. L. *et al.* Synthesis and single enzyme activity of a clicked lipase-BSA hetero-dimer. *J. Appl. Toxicol.* 34, 105–112 (2014).

43. Yeldag, G., Rice, A. & Del Rio Hernandez, A. Chemoresistance and the Self-Maintaining Tumor Microenvironment. *Cancers (Basel)* 10 (2018).

44. Lv, P. C. *et al.* Design, synthesis and biological evaluation of chrysins long-chain derivatives as potential anticancer agents. *Bioorg. Med. Chem.* 18, 1117–1123 (2010).

45. Hatzakis, N. S. *et al.* Synthesis and single enzyme activity of a clicked lipase-BSA hetero-dimer. *Chem. Commun. (Camb.)*, 2012–2014 (2006).

46. Meier, J. L., Mercer, A. C., Rivera, H. Jr. & Burkart, M. D. Synthesis and evaluation of bioorthogonal pantetheine analogues for in vivo protein modification. *J. Am. Chem. Soc.* 128, 12174–12184 (2006).

**Acknowledgements**

This work was supported in part by JSPS KAKENHI Grant Number 19H03373 (A.I.) and the grants from the Takahashi Sangyo-Keizai Research Foundation, Takeda Science Foundation, Ogawa Science and Technology Foundation, and Smoking Research Foundation (to A.I.), and collaborative research grant from API Co., Ltd.

**Author Contributions**

R.M., H.E., R.A. and S.H. conducted experiments and analyzed the data. T.F., M.T., S.E. and K.I. contributed to the experimental plan and discussion of the manuscript. A.I. supervised the project, interpreted data, and wrote the paper. All authors reviewed the results and approved the final version of the manuscript.

**Additional Information**

**Supplementary information** accompanies this paper at https://doi.org/10.1038/s41598-019-50276-z.

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2019